TEM
Tempus AI, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$64.34
−0.59%Oct 19, 2026, 12:30 UTC
Tempus AI announced study results showing its AI-enabled pre-screening panel achieved greater than 80% sensitivity across 12 biomarkers in patients with advanced non-small cell lung cancer, exceeding 90% for several biomarkers.
Source:Oct 15, 2026, 20:01 UTC
Tempus AI announced that it will report its third-quarter 2026 financial results before U.S. markets open on November 2, 2026, and host a conference call and webcast at 8:45 a.m. ET.
Source:Oct 12, 2026, 16:51 UTC
Tempus AI, Inc. expanded its strategic collaborations with Moderna, Inc., Merck & Co., Inc. and RECURSION PHARMACEUTICALS, INC. to advance its precision medicine business.
Source:Oct 5, 2026, 16:06 UTC
Tempus AI is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
Source:Oct 1, 2026, 12:34 UTC
Tempus AI announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology Congress 2026, to be held October 23–27 in Madrid.
Source:Sep 28, 2026, 12:00 UTC
Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI product that analyzes 12-lead resting ECGs to detect signs of undiagnosed moderate or severe mitral regurgitation.
Source:Sep 22, 2026, 19:00 UTC
MAHA Center, a nonprofit tied to HHS Secretary Robert F. Kennedy Jr., solicited corporate sponsorship payments of up to $300,000 for the Sept. 29 MAHA Summit in exchange for access to top U.S. health officials including Kennedy and CMS head Mehmet Oz.
Source:Sep 21, 2026, 13:07 UTC
Recursion Pharmaceuticals and Tempus AI extended their data collaboration agreement.
Sep 19, 2026, 01:46 UTC
Tempus AI CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of Class A Common Stock for approximately $16.1 million on September 17, 2026, under a Rule 10b5-1 trading plan adopted on March 8, 2026.
Source:Sep 19, 2026, 01:45 UTC
Andrew Polovin, Executive Vice President and Chief Legal Officer of Tempus AI, Inc., sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 19, 2026, 01:45 UTC
Tempus AI Chief Accounting Officer Ryan M. Bartolucci sold 7,062 shares of Class A common stock for $529,650 on September 17, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 18, 2026, 13:30 UTC
Tempus AI stock jumped to $80, up 95% from its lowest level this year, reaching its highest level since November last year with a market capitalization above $14 billion.
Source:Sep 18, 2026, 11:50 UTC
Tempus AI shares jumped 14.9% in the last trading session on above-average volume.
Source:Sep 9, 2026, 16:01 UTC
ARPA-H announced the first batch of awards totaling $62.7 million to develop FDA-authorized AI for heart failure treatment, with $33.7 million committed for the first year.
Source:Aug 22, 2026, 07:03 UTC
Tempus AI shares rose 8.3% in mid-day trading on Friday after BTIG Research raised its price target from $70.00 to $80.00.
Source:Aug 20, 2026, 07:24 UTC
Bank of America Corp DE reduced its stake in Tempus AI, Inc. by 63.6% during the quarter, selling 725,709 shares and retaining 414,780 shares, as disclosed in its 13F filing with the SEC.
Source:Aug 4, 2026, 18:04 UTC
Wohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.
Source:Jul 20, 2026, 12:31 UTC
TEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.
Jun 9, 2026, 10:00 UTC
Ambry Genetics announced peer-reviewed research demonstrating the potential of its ExomeReveal RNA testing to improve diagnostic clarity in exome testing.
Source:Jun 3, 2026, 12:30 UTC
Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center launched a digital pathology open-source consortium.
Source:May 31, 2026, 12:30 UTC
Tempus AI, Inc. launched the next-generation of its Lens agentic AI platform for oncology drug development.
Source:May 30, 2026, 12:30 UTC
Tempus AI launched the PRECISION Challenge, a national program providing access to its foundation model, data, and funding to accelerate oncology research.
May 30, 2026, 12:00 UTC
Tempus AI, Inc. launched Tempus Preview, an application that provides rapid preliminary genomic insights within 24 hours of tissue receipt for precision oncology workflows.
Source: